Bio-Techne Corp (TECH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.44B
Last updated: Nov 17, 2026 at 11:06 AM ET
Bio-Techne Corp (TECH) Stock Forecast
Analysts expect Bio-Techne (TECH) to earn $2.03 per share in the fiscal year ending Jun 30, 2027, on revenue of $1.28B. Of 13 analysts, 0 rate the stock Buy or Strong Buy, 12 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Jun 30, 2027 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 3.08, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 8% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 12 | 92.3% |
| Sell | 1 | 7.7% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 13.8% and revenue estimates rise 9.4%.
- Fiscal year ending Jun 30, 2027
- $2.03
- EPS consensus, revenue $1.28B
- Fiscal year ending Jun 30, 2028
- $2.31
- EPS consensus, revenue $1.40B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Jun 30, 2027 | $2.03 | $1.99 to $2.07 | 6 | $1.28B | $1.28B to $1.29B | 4 |
| Jun 30, 2028 | $2.31 | $2.03 to $2.60 | 10 | $1.40B | $1.35B to $1.50B | 9 |
Quarterly Estimates
Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Dec 31, 2026, at $0.48, and highest for the quarter ending Jun 30, 2027, at $0.58.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.48 | $0.46 to $0.51 | 7 | $308.14M | $303.67M to $313.28M | 8 |
| Mar 31, 2027 | $0.56 | $0.55 to $0.59 | 7 | $328.49M | $323.30M to $334.77M | 8 |
| Jun 30, 2027 | $0.58 | $0.53 to $0.62 | 10 | $342.51M | $321.54M to $361.63M | 12 |
Estimate Revisions
Across the 4 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Jun 30, 2027 | 0 | 1 |
| Fiscal year ending Jun 30, 2028 | 3 | 0 |
| Quarter ending Dec 31, 2026 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has fallen 0.5% from $2.04.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Jun 30, 2027 | $2.03 | $2.04 | $2.02 | $2.02 | $2.04 | -0.7% |
| Fiscal year ending Jun 30, 2028 | $2.31 | $2.31 | $2.31 | $2.31 | $2.30 | +0.4% |
| Quarter ending Dec 31, 2026 | $0.48 | $0.48 | $0.48 | $0.47 | $0.48 | 0.0% |
| Quarter ending Mar 31, 2027 | $0.56 | $0.56 | $0.56 | $0.55 | $0.56 | +0.5% |
Frequently Asked Questions About TECH
What is the TECH stock forecast?
Consensus analyst estimates put Bio-Techne's EPS at $2.03 for the fiscal year ending Jun 30, 2027, on revenue of $1.28B. The consensus rating from 13 analysts is Hold.
How do analysts rate TECH stock?
Of 13 analysts covering Bio-Techne, 0 rate it Strong Buy, 0 Buy, 12 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from TECH next year?
For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is $2.03, with estimates from $1.99 to $2.07 from 6 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is $2.31, with estimates from $2.03 to $2.60 from 10 analysts.
What revenue do analysts expect from Bio-Techne next year?
For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $1.28B, with estimates from $1.28B to $1.29B. For the fiscal year ending Jun 30, 2028, the consensus revenue estimate is $1.40B, with estimates from $1.35B to $1.50B.
How many analysts cover TECH?
13 analysts rate Bio-Techne stock, and 6 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.
TECH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors